Brief: Travere Therapeutics Submits sNDA To FDA For Approval Of Filspari (Sparsentan) For The Treatment Of FSGS

Travere Therapeutics

17/03/2025 11:20

March 17 (Reuters) - Travere Therapeutics Inc TVTX.O:

TRAVERE THERAPEUTICS SUBMITS SNDA TO FDA FOR APPROVAL OF FILSPARI® (SPARSENTAN) FOR THE TREATMENT OF FSGS

TRAVERE THERAPEUTICS INC: FDA NOTIFIED COMPANY THAT REMS MONITORING FOR EMBRYO-FETAL TOXICITY IS NO LONGER NECESSARY

TRAVERE THERAPEUTICS INC: PLANS TO SUBMIT AMENDMENT TO REMS SNDA CURRENTLY UNDER REVIEW FOR MODIFICATION OF LIVER MONITORING

TRAVERE THERAPEUTICS INC: CONTINUES TO EXPECT A REMS MODIFICATION PDUFA TARGET ACTION DATE OF AUGUST 28

Source text: ID:nGNX583jwH

Further company coverage: TVTX.O

 ((Reuters.Briefs@thomsonreuters.com))